Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Epidemiology

Background:

• Animal studies indicate Angiotensin-converting enzyme (ACE) inhibitors can prevent aortic aneurysm expansion and rupture.
• Clinical evidence is needed to confirm the association between ACE inhibitors and abdominal aortic aneurysm (AAA) rupture in human patients.

Purpose of the Study:

• To investigate the association between ACE inhibitor use and the risk of rupture in patients diagnosed with abdominal aortic aneurysms.

Main Methods:

• A population-based case-control study was conducted using linked administrative databases in Ontario, Canada.
• The study included 15,326 patients aged over 65 admitted with a diagnosis of ruptured or intact abdominal aortic aneurysm between 1992 and 2002.

Main Results:

• Patients using ACE inhibitors prior to hospital admission showed a significantly lower likelihood of presenting with a ruptured aneurysm (OR 0.82).
• This protective association remained consistent after adjusting for various demographic factors, comorbidities, and healthcare utilization.
• No similar protective associations were observed for other antihypertensive drug classes, including beta blockers, calcium channel blockers, and diuretics.

Conclusions:

• ACE inhibitors are associated with a reduced risk of abdominal aortic aneurysm rupture.
• Unlike other antihypertensive agents, ACE inhibitors demonstrate a potential protective role in AAA rupture.
• Randomized controlled trials investigating ACE inhibitors for AAA rupture prevention are warranted.